Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

Nicole L. Yates; Hua Xin Liao; Youyi Fong; Allan DeCamp; Nathan A. Vandergrift; William T. Williams; S. Munir Alam; Guido Ferrari; Zhi Yong Yang; Kelly E. Seaton; Phillip W. Berman; Michael D. Alpert; David T. Evans; Robert J. O'Connell; Donald Francis; Faruk Sinangil; Carter Lee; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Abraham Pinter; Susan Zolla-Pazner; Peter B. Gilbert; Gary J. Nabel; Nelson L. Michael; Jerome H. Kim; David C. Montefiori; Barton F. Haynes; Georgia D. Tomaras

doi:10.1126/scitranslmed.3007730

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

Nicole L. Yates, Hua Xin Liao, Youyi Fong, Allan DeCamp, Nathan A. Vandergrift, William T. Williams, S. Munir Alam, Guido Ferrari, Zhi Yong Yang, Kelly E. Seaton, Phillip W. Berman, Michael D. Alpert, David T. Evans, Robert J. O'Connell, Donald Francis, Faruk Sinangil, Carter Lee, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit KaewkungwalPunnee Pitisuttithum, James Tartaglia, Abraham Pinter, Susan Zolla-Pazner, Peter B. Gilbert, Gary J. Nabel, Nelson L. Michael, Jerome H. Kim, David C. Montefiori, Barton F. Haynes, Georgia D. Tomaras

Research output: Contribution to journal › Article › peer-review

299 Scopus citations

Abstract

HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.

Original language	English (US)
Article number	228ra39
Journal	Science Translational Medicine
Volume	6
Issue number	228
DOIs	https://doi.org/10.1126/scitranslmed.3007730
State	Published - Mar 19 2014
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1126/scitranslmed.3007730

Cite this

Yates, N. L., Liao, H. X., Fong, Y., DeCamp, A., Vandergrift, N. A., Williams, W. T., Alam, S. M., Ferrari, G., Yang, Z. Y., Seaton, K. E., Berman, P. W., Alpert, M. D., Evans, D. T., O'Connell, R. J., Francis, D., Sinangil, F., Lee, C., Nitayaphan, S., Rerks-Ngarm, S., ... Tomaras, G. D. (2014). Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Science Translational Medicine, 6(228), Article 228ra39. https://doi.org/10.1126/scitranslmed.3007730

Yates, NL, Liao, HX, Fong, Y, DeCamp, A, Vandergrift, NA, Williams, WT, Alam, SM, Ferrari, G, Yang, ZY, Seaton, KE, Berman, PW, Alpert, MD, Evans, DT, O'Connell, RJ, Francis, D, Sinangil, F, Lee, C, Nitayaphan, S, Rerks-Ngarm, S, Kaewkungwal, J, Pitisuttithum, P, Tartaglia, J, Pinter, A, Zolla-Pazner, S, Gilbert, PB, Nabel, GJ, Michael, NL, Kim, JH, Montefiori, DC, Haynes, BF & Tomaras, GD 2014, 'Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination', Science Translational Medicine, vol. 6, no. 228, 228ra39. https://doi.org/10.1126/scitranslmed.3007730

@article{c38fba7f27a04d5f9bee81fe662e6c10,

title = "Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination",

abstract = "HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.",

author = "Yates, {Nicole L.} and Liao, {Hua Xin} and Youyi Fong and Allan DeCamp and Vandergrift, {Nathan A.} and Williams, {William T.} and Alam, {S. Munir} and Guido Ferrari and Yang, {Zhi Yong} and Seaton, {Kelly E.} and Berman, {Phillip W.} and Alpert, {Michael D.} and Evans, {David T.} and O'Connell, {Robert J.} and Donald Francis and Faruk Sinangil and Carter Lee and Sorachai Nitayaphan and Supachai Rerks-Ngarm and Jaranit Kaewkungwal and Punnee Pitisuttithum and James Tartaglia and Abraham Pinter and Susan Zolla-Pazner and Gilbert, {Peter B.} and Nabel, {Gary J.} and Michael, {Nelson L.} and Kim, {Jerome H.} and Montefiori, {David C.} and Haynes, {Barton F.} and Tomaras, {Georgia D.}",

year = "2014",

month = mar,

day = "19",

doi = "10.1126/scitranslmed.3007730",

language = "English (US)",

volume = "6",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "228",

}

TY - JOUR

T1 - Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

AU - Yates, Nicole L.

AU - Liao, Hua Xin

AU - Fong, Youyi

AU - DeCamp, Allan

AU - Vandergrift, Nathan A.

AU - Williams, William T.

AU - Alam, S. Munir

AU - Ferrari, Guido

AU - Yang, Zhi Yong

AU - Seaton, Kelly E.

AU - Berman, Phillip W.

AU - Alpert, Michael D.

AU - Evans, David T.

AU - O'Connell, Robert J.

AU - Francis, Donald

AU - Sinangil, Faruk

AU - Lee, Carter

AU - Nitayaphan, Sorachai

AU - Rerks-Ngarm, Supachai

AU - Kaewkungwal, Jaranit

AU - Pitisuttithum, Punnee

AU - Tartaglia, James

AU - Pinter, Abraham

AU - Zolla-Pazner, Susan

AU - Gilbert, Peter B.

AU - Nabel, Gary J.

AU - Michael, Nelson L.

AU - Kim, Jerome H.

AU - Montefiori, David C.

AU - Haynes, Barton F.

AU - Tomaras, Georgia D.

PY - 2014/3/19

Y1 - 2014/3/19

N2 - HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.

AB - HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.

UR - http://www.scopus.com/inward/record.url?scp=84899087118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899087118&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3007730

DO - 10.1126/scitranslmed.3007730

M3 - Article

C2 - 24648342

AN - SCOPUS:84899087118

SN - 1946-6234

VL - 6

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 228

M1 - 228ra39

ER -

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this